Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert E. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh A. Huseni, Susheela Carroll, Roxana Ioana Sufan, Christina Schiff, Michael B. Atkins
Institutions: Cleveland Clinic, Memorial Sloan Kettering Cancer Center, Queen Mary University of London, The Royal Free Hospital, Barts Cancer Institute, Beth Israel Deaconess Medical Center, Institut Gustave Roussy, Aarhus University Hospital, The Christie Hospital, The Christie NHS Foundation Trust, Azienda Ospedaliera S.Maria, University of Tübingen, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Policlinico San Matteo Fondazione, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, MD Anderson Cancer Center Madrid, Genentech, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947076930